Financials data is unavailable for this security.
View more
Year on year Bolt Biotherapeutics Inc grew revenues 37.48% from 5.73m to 7.88m while net income improved from a loss of 88.10m to a smaller loss of 69.20m.
| Gross margin | -- |
|---|---|
| Net profit margin | -592.57% |
| Operating margin | -653.44% |
| Return on assets | -42.03% |
|---|---|
| Return on equity | -58.04% |
| Return on investment | -47.37% |
More ▼
Cash flow in USDView more
In 2023, Bolt Biotherapeutics Inc increased its cash reserves by 16.34%, or 1.77m. Cash Flow from Investing totalled 71.04m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 69.53m for operations while cash generated from financing totalled 253.00k.
| Cash flow per share | -1.69 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.24 |
|---|---|
| Tangible book value per share | 2.24 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.28 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
